Pharmacokinetics

Human randomized studyAbstract inspected

A small crossover study in six healthy volunteers given intravenous and oral N-acetylcysteine found different pharmacokinetics depending on the analyte measured: reduced (parent-thiol) NAC had an intravenous terminal half-life of 1.95 hours and oral bioavailability of 4.0%, while total NAC (including disulfide-bound forms) had a terminal half-life of 5.58 hours intravenously and 6.25 hours orally, with 9.1% oral bioavailability. A single unqualified NAC half-life obscures this analytical distinction.^[1]

Small (n=6) pharmacokinetic study; laboratory analyte and administration route matter, and no organ-protection endpoint was tested.
Abstract-checked; no qualified clinical review.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.

2026-09-09 · Reopened the PubMed structured abstract via E-utilities and added exact half-life and bioavailability values for reduced versus total NAC. No PMC full text available. Independent editorial review pending; no qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.
Olsson B, Johansson M, Gabrielsson J, Bolme P. Eur J Clin Pharmacol. 1988;34(1):77-82. 1988. PMID:3360052 Abstract only.
Inspected location: PubMed abstract (full structured text): reduced-NAC and total-NAC volume of distribution, clearance, terminal half-life and oral bioavailability after IV and oral dosing
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

Fresh PubMed EUtils retrieval for inherited lead PMID 3360052; identity, abstract and linked corrections checked where an abstract existed.
https://pubmed.ncbi.nlm.nih.gov/3360052/ — abstract; PubMed abstract: Results: reduced versus total N-acetylcysteine pharmacokinetic measures after intravenous and oral exposure

View this compound in the research library →

Related records in this class

Grouped under Ancillary compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.